Inactivation of p53 found in more than half of human cancers is often associated with increased tumor resistance to anti-cancer therapy. We have previously shown that overexpression of the ...

DNA damage is carried over in p53-depleted cells from one cell cycle to the next. In p53-proficient cells, low levels of DNA damage after WEE1 inhibition are tolerated as cells manage to repair the ...

The tumour suppressor p53 is a crucial regulator of cell cycle arrest and apoptosis by acting as a transcription factor to regulate a variety of genes. At least in part, this control is exerted by ...

Background: AZD1775 (formerly MK-1775) is a potent and selective inhibitor of Wee1, a kinase that phosphorylates CDC2. Phosphorylation of CDC2 inactivates the CDC2/cyclin B complex and is therefore ...

Results: Wee1 inhibition combined with single or Fx IR increased TGD of p53 deficient (but not p53 wt) tumors supra-additively. The best combination consisted of Fx IR combined with Wee1 inhibitor ...

WEE1 is a kinase that has a key role in regulating the G2-M checkpoint of the cell cycle. ... P53, as I mentioned earlier, plays a major role in regulating this checkpoint.

VANCOUVER, B.C., June 2, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it ...

Schrödinger today reported new preclinical data supporting advancement of its Wee1 Inhibitor Program at AACR 2022 Annual Meeting.

Following the FDA decision, Zentalis’ stock was up by 53%, from $3.24 at closing on 13 September to $4.96 at the market opening on 16 September.

A year after getting Pfizer’s backing, Zentalis Pharmaceuticals says new data for a WEE1 candidate justifies putting the asset into a phase 3 study for ovarian cancer next year.. The phase 1b ...

CHICAGO, April 28, 2025--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research ...